Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Body Weight D001835 333 associated lipids
Lung Neoplasms D008175 171 associated lipids
Adenocarcinoma D000230 166 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Edema D004487 152 associated lipids
Carcinoma, Hepatocellular D006528 140 associated lipids
Hemolysis D006461 131 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Inflammation D007249 119 associated lipids
Hypertension D006973 115 associated lipids
Glioma D005910 112 associated lipids
Weight Gain D015430 101 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Brain Ischemia D002545 89 associated lipids
Seizures D012640 87 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Arteriosclerosis D001161 86 associated lipids
Atherosclerosis D050197 85 associated lipids
Pancreatic Neoplasms D010190 77 associated lipids
Alzheimer Disease D000544 76 associated lipids
Stomach Ulcer D013276 75 associated lipids
Leukemia D007938 74 associated lipids
Coronary Disease D003327 70 associated lipids
Melanoma D008545 69 associated lipids
Colitis D003092 69 associated lipids
Liver Cirrhosis D008103 67 associated lipids
Mammary Neoplasms, Experimental D008325 67 associated lipids
Neuroblastoma D009447 66 associated lipids
Reperfusion Injury D015427 65 associated lipids
Cystic Fibrosis D003550 65 associated lipids
Pain D010146 64 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Weight Loss D015431 56 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Nerve Degeneration D009410 53 associated lipids
Parkinson Disease D010300 53 associated lipids
Asthma D001249 52 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Osteosarcoma D012516 50 associated lipids
Thrombosis D013927 49 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Psoriasis D011565 47 associated lipids
Metabolism, Inborn Errors D008661 46 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Leukemia, Experimental D007942 42 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Hyperalgesia D006930 42 associated lipids
Hypotension D007022 41 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Arthritis D001168 41 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Zellweger Syndrome D015211 39 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Peritonitis D010538 38 associated lipids
Nervous System Diseases D009422 37 associated lipids
Lung Diseases D008171 37 associated lipids
Liver Cirrhosis, Experimental D008106 36 associated lipids
Fever D005334 35 associated lipids
Glomerulonephritis D005921 35 associated lipids
Anaphylaxis D000707 35 associated lipids
Epilepsy D004827 35 associated lipids
Infarction, Middle Cerebral Artery D020244 35 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Burns D002056 34 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Spinal Cord Injuries D013119 34 associated lipids
Thyroid Neoplasms D013964 33 associated lipids
Memory Disorders D008569 33 associated lipids
Uremia D014511 33 associated lipids
Acute Lung Injury D055371 33 associated lipids
Hypertension, Pulmonary D006976 32 associated lipids
Stroke D020521 32 associated lipids
Neurodegenerative Diseases D019636 32 associated lipids
Cardiomegaly D006332 31 associated lipids
Endometrial Neoplasms D016889 30 associated lipids
Proteinuria D011507 30 associated lipids
Vitamin E Deficiency D014811 29 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Neuralgia D009437 28 associated lipids
Endotoxemia D019446 27 associated lipids
Angina Pectoris D000787 27 associated lipids
Hyperinsulinism D006946 27 associated lipids
Brain Diseases D001927 27 associated lipids
Gastritis D005756 27 associated lipids
Mammary Neoplasms, Animal D015674 27 associated lipids
Gastrointestinal Hemorrhage D006471 27 associated lipids
Encephalomyelitis, Autoimmune, Experimental D004681 26 associated lipids
Nasal Polyps D009298 26 associated lipids
Ascites D001201 25 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Leukemia-Lymphoma, Adult T-Cell D015459 25 associated lipids
Pseudomonas Infections D011552 25 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Pulmonary Fibrosis D011658 24 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Leslie CC and Detty DM Arachidonic acid turnover in response to lipopolysaccharide and opsonized zymosan in human monocyte-derived macrophages. 1986 Biochem. J. pmid:3098232
Lewis RE and Granger HJ Neutrophil-dependent mediation of microvascular permeability. 1986 Fed. Proc. pmid:3510911
DeFeudis FV Studies on endothelium-dependent vasorelaxation. 1986 Gen. Pharmacol. pmid:3512363
Wardlow ML et al. Substrate specificity and partial characterization of the PAF-acylhydrolase in human serum that rapidly inactivates platelet-activating factor. 1986 J. Immunol. pmid:3514760
Böhm R and Giessler AJ [Thrombocyte aggregation inhibitors. A new class of active substances]. 1986 Pharmazie pmid:3515372
Touvay C et al. Characterization of platelet activating factor (PAF)-acether-induced contractions of guinea-pig lung strips by selected inhibitors of arachidonic acid metabolism and by PAF-acether antagonists. 1986 Immunopharmacology pmid:3021651
Siffert W et al. Inhibition of platelet aggregation by amiloride. 1986 Thromb. Res. pmid:3787567
Whittle BJ et al. Microvascular actions of platelet-activating factor on rat gastric mucosa and submucosa. 1986 Am. J. Physiol. pmid:3789144
Suemune H et al. Enzymatic synthesis of 2,3-O-isopropylidene-sn-glycerol, a chiral building block for platelet-activating factor. 1986 Chem. Pharm. Bull. pmid:3791517
Silva PM et al. Platelet involvement in rat paw edema induced by 2-methoxy-PAF. 1986 Inflammation pmid:3793206
Wu MS et al. Inhibition of the platelet activating factor (PAF)-induced in vivo responses in rats by trans-2,5-(3,4,5-trimethoxyphenyl) tetrahydrofuran (L-652,731), a PAF receptor antagonist. 1986 J. Pharmacol. Exp. Ther. pmid:3795043
Page CP et al. Inflammatory mediators of asthma. 1986 Eur J Respir Dis Suppl pmid:3527737
Mlczoch J [Disorders of thrombocyte function and/or endothelial cell damage as a cause of primary pulmonary hypertension?]. 1986 Herz pmid:3530927
Lovett DH and Sterzel RB Cell culture approaches to the analysis of glomerular inflammation. 1986 Kidney Int. pmid:3531678
Muirhead EE et al. Renal medullary system of blood pressure control. 1986 J Hypertens Suppl pmid:3534182
Foegh ML et al. The causal role of PAF and leukotrienes in acute cardiac allograft rejection in rats. 1986 Pharmacol Res Commun pmid:3534895
Zimmerman GA and Klein-Knoeckel D Human endothelial cells inhibit granulocyte aggregation in vitro. 1986 J. Immunol. pmid:3009611
Sage SO and Rink TJ Effects of ionic substitution on [Ca2+]i rises evoked by thrombin and PAF in human platelets. 1986 Eur. J. Pharmacol. pmid:3758190
Chignard M et al. Use of steroidal antiinflammatory drug provides further evidence for a potential role of PAF-acether in bronchial anaphylaxis. 1986 Int. Arch. Allergy Appl. Immunol. pmid:3759260
Ohno M et al. Molecular design toward biologically significant compounds based on platelet activating factor: a highly selective agonist as a potential antihypertensive agent. 1986 J. Med. Chem. pmid:3761300
Parnham MJ and Bittner C Pharmacological analysis of guinea-pig macrophage chemiluminescence responses to platelet activating factor and opsonized zymosan. 1986 Int. J. Immunopharmacol. pmid:3804536
Handley DA et al. Vascular responses of platelet-activating factor in the Cebus apella primate and inhibitory profiles of antagonists SRI 63-072 and SRI 63-119. 1986 Immunopharmacology pmid:3733419
Issekutz AC and Szpejda M Evidence that platelet activating factor may mediate some acute inflammatory responses. Studies with the platelet-activating factor antagonist, CV3988. 1986 Lab. Invest. pmid:3951199
Shukla SD Action of phosphatidylinositol specific phospholipase C on platelets: nonlytic release of acetylcholinesterase, effect on thrombin and PAF induced aggregation. 1986 Life Sci. pmid:3951330
Benveniste J Paf-acether (platelet-activating factor). 1986 Bull Eur Physiopathol Respir pmid:3955269
Phillips ML and Bonjouklian R Cyclic platelet-activating factor analogues derived from 2-deoxy-D-erythro-pentose. 1986 Carbohydr. Res. pmid:3955572
Schneider E et al. Transbilayer reorientation of platelet-activating factor in the erythrocyte membrane. 1986 FEBS Lett. pmid:3956740
Thomas MJ et al. Desorption chemical ionization mass spectrometry of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholines and analogues. 1986 J. Lipid Res. pmid:3958619
Becker EL et al. Pertussis toxin as a probe of neutrophil activation. 1986 Fed. Proc. pmid:3011523
Ozaki Y et al. Oxygen radical production by neutrophils from patients with bacterial infection and rheumatoid arthritis. Measurement of hydrogen peroxide may most accurately represent enhancement of oxygen radical production during infection. 1986 Inflammation pmid:3011666
Doebber TW et al. Platelet-activating factor (PAF) mediation of rat anaphylactic responses to soluble immune complexes. Studies with PAF receptor antagonist L-652,731. 1986 J. Immunol. pmid:3011900
Tokumura A et al. Alkylacetylglycerophosphocholine effects on the metabolism of phospholipids in rabbit platelets: effects of extracellular Ca2+ and prostacyclin. 1986 Arch. Biochem. Biophys. pmid:3013094
Houslay MD et al. Platelet activating factor and U44069 stimulate a GTPase activity in human platelets which is distinct from the guanine nucleotide regulatory proteins, Ns and Ni. 1986 Biochem. J. pmid:3013161
Ban C et al. Metabolism of platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine) in human fetal membranes and decidua vera. 1986 Arch. Biochem. Biophys. pmid:3963833
Cerletti C et al. Platelet-aggregation response to single or paired aggregating stimuli after low-dose aspirin. 1986 N. Engl. J. Med. pmid:3941724
Parente L et al. The effect of glucocorticoids on lyso-PAF formation in vitro and in vivo. 1986 Agents Actions pmid:3962774
Tarayre JP et al. Inflammatory action of PAF-acether in the rat pleural cavity. 1986 Agents Actions pmid:3962789
Blank ML et al. Metabolism of platelet activating factor (1-alkyl-2-acetyl-sn-glycero-3-phosphocholine) and 1-alkyl-2-acetyl-sn-glycerol by human endothelial cells. 1986 Biochim. Biophys. Acta pmid:3707974
Tarayre JP et al. Exudative, cellular and humoral reactions to platelet-activating factor (PAF-acether) in the pleural cavity of rats. 1986 Eur. J. Pharmacol. pmid:3755401
Kikawa Y et al. Leukotriene B4 biosynthesis in polymorphonuclear leukocytes from blood of umbilical cord, infants, children, and adults. 1986 Pediatr. Res. pmid:3012451
Bussolino F et al. Production of platelet-activating factor by chick retina. 1986 J. Biol. Chem. pmid:3023352
Mossmann H et al. Effect of platelet-activating factor on human polymorphonuclear leukocyte enhancement of chemiluminescence and antibody-dependent cellular cytotoxicity. 1986 J. Leukoc. Biol. pmid:3455715
Haye-Legrand I et al. Production of PAF-acether and leukotrienes by cultured mouse macrophages. 1986 Pharmacol Res Commun pmid:3774848
Dupont L et al. Crystal and molecular structure of BN 52021, a PAF-acether antagonist. Comparison with the conformation of Kadsurenone and related compounds. 1986 Pharmacol Res Commun pmid:3774849
Bruynzeel PL et al. Platelet-activating factor (PAF-acether) induced leukotriene C4 formation and luminol dependent chemiluminescence by human eosinophils. 1986 Pharmacol Res Commun pmid:3774850
Etienne A et al. The relative role of PAF-acether and icosanoids in septic shock. 1986 Pharmacol Res Commun pmid:3774851
Maes L et al. Endogenic PAF-acether production by guinea pig endothelial cells in experimental arterial thrombosis. 1986 Pharmacol Res Commun pmid:3774852
Lee TC et al. A new de novo pathway for the formation of 1-alkyl-2-acetyl-sn-glycerols, precursors of platelet activating factor. Biochemical characterization of 1-alkyl-2-lyso-sn-glycero-3-P:acetyl-CoA acetyltransferase in rat spleen. 1986 J. Biol. Chem. pmid:3007498
Handley DA et al. Inhibition of PAF-induced systemic responses in the rat, guinea pig, dog and primate by the receptor antagonist SRI 63-441. 1986 Thromb. Haemost. pmid:3775689
Hwang SB and Lam MH Species difference in the specific receptors of platelet activating factor. 1986 Biochem. Pharmacol. pmid:3024653